Status:

RECRUITING

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Lead Sponsor:

Eli Lilly and Company

Conditions:

Asthma

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will l...

Eligibility Criteria

Inclusion

  • Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit.
  • Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2 out of 3 visits before randomization.
  • History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit.

Exclusion

  • Participants are excluded from the study if any of the following criteria apply:
  • An established diagnosis of occupational asthma
  • Known pre-existing, clinically important lung condition other than asthma, including but not limited to:
  • chronic respiratory infection
  • bronchiectasis
  • pulmonary fibrosis
  • allergic bronchopulmonary aspergillosis
  • emphysema
  • chronic bronchitis
  • eosinophilic granulomatosis with polyangiitis
  • chronic obstructive pulmonary disease, and
  • other mimics of asthma, that is, vocal cord dysfunction.
  • Have a current or recent acute, active infection. For at least 30 days before screening visit and up to the randomization visit.

Key Trial Info

Start Date :

October 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

531 Patients enrolled

Trial Details

Trial ID

NCT07219173

Start Date

October 22 2025

End Date

June 1 2028

Last Update

December 18 2025

Active Locations (120)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 30 (120 locations)

1

AMR Clinical

Tempe, Arizona, United States, 85281

2

NewportNativeMD, Inc.

Newport Beach, California, United States, 92663

3

California Medical Research Associates

Northridge, California, United States, 91324

4

Peninsula Research Associates

Rolling Hills Estates, California, United States, 90274